Literature DB >> 10372735

Endometrial and myometrial expression of nitric oxide synthase isoforms in pre- and postmenopausal women.

O Khorram1, M Garthwaite, R R Magness.   

Abstract

Expression of nitric oxide synthase (NOS) protein was examined by Western immunoblot analysis and immunohistochemistry in the endometrium and myometrium of 19 premenopausal and 18 postmenopausal women undergoing hysterectomy for benign gynecological reasons. The predominant isoform of NOS in the human uterus was endothelial NOS (eNOS). Using immunohistochemistry, eNOS was localized predominantly to the glandular epithelium and endometrial microvascular endothelium. eNOS was scant and inconsistently detected in endometrial stromal cells. In the myometrium, eNOS was predominantly found in smooth muscle cells (myocytes) and was also detected in the microvascular endothelium. Neuronal NOS was not detectable by immunohistochemical techniques, and inducible NOS (iNOS) was only detectable in occasional specimens, although more often in secretory specimens. iNOS, when present, was predominantly found in glandular epithelium and occasional stromal cells. Myometrial iNOS was scant and not consistently detected. By Western immunoblot analysis, neuronal NOS or iNOS was not detected. We observed a unique menstrual cycle-dependent expression of eNOS that was different in the endometrium compared to the myometrium and was independent of uterine pathology. In the endometrium, there was 62% higher expression of eNOS during the secretory phase (P = 0.00085) compared to the proliferative phase, whereas in the myometrium, there was 74% greater expression of eNOS in the proliferative phase (P = 0.03) compared to the secretory phase. Within the secretory phase, maximal endometrial eNOS expression was found in the midportion, whereas in the myometrium, highest eNOS expression occurred during the late secretory phase. In postmenopausal women not treated with hormones, a significant reduction in endometrial and myometrial expression of eNOS occurred, which was reversed by continuous hormone replacement therapy. In summary, both endogenous ovarian steroids and exogenous sex hormones influence uterine eNOS expression. Our results suggest that estrogen may regulate myometrial eNOS, whereas progesterone or a combination of estrogen and progesterone may be more important in regulating endometrial eNOS, and NO may be a critical mediator of sex steroid actions in the human uterus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372735     DOI: 10.1210/jcem.84.6.5759

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Nitric oxide and its role in blastocyst implantation.

Authors:  Omid Khorram
Journal:  Rev Endocr Metab Disord       Date:  2002-05       Impact factor: 6.514

2.  In vitro responsiveness of human post-menopausal myometrium to endothelin-1 and ovarian steroids.

Authors:  E Domali; P A Molyvdas; I E Messinis
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

3.  Altered endometrial expression of endothelial nitric oxide synthase in women with unexplained recurrent miscarriage and infertility.

Authors:  Tohid Najafi; Marefat Ghaffari Novin; Reza Ghazi; Omid Khorram
Journal:  Reprod Biomed Online       Date:  2012-07-20       Impact factor: 3.828

4.  Association of CAV1/CAV2 genomic variants with primary open-angle glaucoma overall and by gender and pattern of visual field loss.

Authors:  Stephanie J Loomis; Jae H Kang; Robert N Weinreb; Brian L Yaspan; Jessica N Cooke Bailey; Douglas Gaasterland; Terry Gaasterland; Richard K Lee; Paul R Lichter; Donald L Budenz; Yutao Liu; Tony Realini; David S Friedman; Catherine A McCarty; Sayoko E Moroi; Lana Olson; Joel S Schuman; Kuldev Singh; Douglas Vollrath; Gadi Wollstein; Donald J Zack; Murray Brilliant; Arthur J Sit; William G Christen; John Fingert; Peter Kraft; Kang Zhang; R Rand Allingham; Margaret A Pericak-Vance; Julia E Richards; Michael A Hauser; Jonathan L Haines; Louis R Pasquale; Janey L Wiggs
Journal:  Ophthalmology       Date:  2013-10-25       Impact factor: 12.079

5.  The effects of raloxifene hydrochloride on ocular hemodynamics and visual function.

Authors:  Brent Siesky; Alon Harris; Nisha Kheradiya; Rita Ehrlich; Carissa Klaas; Boaris Kaplan; Yara Catoira; Lynne McCranor; Carlos Rospigliosi; Mira Harris
Journal:  Int Ophthalmol       Date:  2008-04-22       Impact factor: 2.031

6.  Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use.

Authors:  Jae Hee Kang; Janey L Wiggs; Bernard A Rosner; Susan E Hankinson; Wael Abdrabou; Bao Jian Fan; Jonathan Haines; Louis R Pasquale
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-08       Impact factor: 4.799

7.  Influence of progesterone on endometrial nitric oxide synthase expression.

Authors:  Omid Khorram; Guang Han
Journal:  Fertil Steril       Date:  2008-08-16       Impact factor: 7.329

Review 8.  Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: promising options for prevention and treatment of uterine fibroids?

Authors:  Md Soriful Islam; Most Mauluda Akhtar; Andrea Ciavattini; Stefano Raffaele Giannubilo; Olga Protic; Milijana Janjusevic; Antonio Domenico Procopio; James H Segars; Mario Castellucci; Pasquapina Ciarmela
Journal:  Mol Nutr Food Res       Date:  2014-06-30       Impact factor: 5.914

9.  Reproductive factors and NOS3 variant interactions in primary open-angle glaucoma.

Authors:  Jae Hee Kang; Janey L Wiggs; Jonathan Haines; Wael Abdrabou; Louis R Pasquale
Journal:  Mol Vis       Date:  2011-09-30       Impact factor: 2.367

10.  Expression and function of Toll-like receptor 4 in the endometrial cells of the uterus.

Authors:  Shan Herath; Deborah P Fischer; Dirk Werling; Erin J Williams; Sonia T Lilly; Hilary Dobson; Clare E Bryant; I Martin Sheldon
Journal:  Endocrinology       Date:  2005-10-13       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.